AERD, Two Ways: When a Cardiac Indication for Aspirin Changes the Calculus
The same diagnosis, the same proposed treatment, and two patients for whom it carries entirely different risk.
Walter H., a 64-year-old retired accountant, has full-blown AERD — asthma, recurrent nasal polyps despite two prior sinus surgeries, and a documented severe respiratory reaction to ibuprofen a decade ago that sent him to the emergency department. He also has coronary artery disease, with a drug-eluting stent placed three years ago, and takes 81mg of aspirin daily indefinitely for cardioprotection — a medication he already can't safely be without, prescribed by a cardiologist who has no reason to know his airway reacts badly to the drug's cousins.
His situation makes the desensitization question categorically different from a patient with no other reason to take aspirin. He is, in effect, already living with a form of the drug in his system every day, at a dose too low to trigger his AERD reaction reliably but also too low to control it — aspirin desensitization would move him to a therapeutic maintenance dose, commonly 650mg twice daily, well above his current cardioprotective regimen, but in a drug class he is not being asked to newly accept, only to take differently. Berges-Gimeno and colleagues' long-term outcomes data on desensitized AERD patients found durable reductions in polyp recurrence and NSAID-reaction risk sustained for as long as maintenance therapy continued — for a patient who will be on some form of daily aspirin for the rest of his life regardless, that durability argument carries unusual weight.
He has well-controlled type 2 diabetes on metformin alone, with no other cardiac risk factors beyond the coronary disease already named, and his cardiologist has confirmed no contraindication to escalating his aspirin dose from a cardiac standpoint. His most recent stress test, performed eight months ago as part of routine surveillance, showed no inducible ischemia, so his cardiac status is stable enough for the conversation. What nobody has yet reconciled is that the cardiologist who committed him to daily aspirin was never told his airway reacts to the drug's cousins — he has spent three years on a medication that a full accounting of his allergy history might have prompted someone to at least ask about.
A drug he already can't safely stop
He's already committed to daily aspirin for the rest of his life for his heart. Desensitizing him and moving to a therapeutic maintenance dose isn't asking him to accept a new drug risk — it's asking him to take a drug he's already on, differently, for a dual benefit. Berges-Gimeno's long-term data show durable reduction in recurrence and NSAID-reaction risk for exactly this population.
I'll concede this is a genuinely different case than the usual AERD desensitization conversation.
The bleeding-risk argument I'd normally raise against committing someone to high-dose maintenance aspirin loses most of its force when he's already going to be on some form of the drug indefinitely — the marginal risk of the higher dose over his current 81mg, given his cardiologist's own comfort with daily aspirin in him already, is smaller than the case for a treatment-naïve patient.
This is exactly the profile where desensitization's cost-benefit tips clearly in its favor — the drug-specific risk being accepted is close to zero marginal, since it's layered onto an indication that already exists independently. I'd coordinate the dose increase directly with his cardiologist rather than treat it as a purely allergy-side decision.
Agreed, without real dissent: proceed with aspirin desensitization, coordinated with his cardiologist, given how directly it serves both his cardiac and AERD needs at once.
Naomi F., a 41-year-old marketing director, has the same underlying disease as Walter — asthma, AERD-pattern nasal polyposis confirmed after two prior surgeries, and a clear history of respiratory reaction to naproxen — but nothing else in her medical history involves aspirin at all. She has no cardiovascular disease, no other indication for antiplatelet therapy, and describes herself as someone who has “never taken a daily pill in my life” before her current sinus medications.
For her, aspirin desensitization would mean accepting a wholly new, lifelong medication risk — gastrointestinal bleeding and ulcer risk from indefinite high-dose maintenance therapy — purely to treat her AERD, with no independent medical reason making that risk one she was going to carry anyway. That changes which trial evidence is actually most relevant to her decision. Dupilumab's own AERD-specific subgroup analysis within the SINUS program (Laidlaw et al.) found meaningful improvement in nasal polyp score and sense of smell in patients with confirmed AERD, without requiring any new aspirin exposure at all — a materially different risk profile for a patient with nothing else pulling her toward accepting that specific drug's risks.
She has no other chronic medical conditions besides her asthma and AERD, takes no regular medications beyond her asthma inhalers, and has never had a gastrointestinal bleed, ulcer, or bleeding disorder of any kind — a clean baseline that means any bleeding risk from high-dose aspirin would be a genuinely new exposure for her, not a modest addition to an already-elevated risk profile the way it might be for an older patient. She works in a demanding client-facing role that leaves little flexibility for a treatment requiring frequent in-office visits during a lengthy desensitization protocol, a logistical reality she raised herself before either physician mentioned scheduling at all. Her asthma, like Walter's, is well-controlled on a standard inhaled regimen, so today's discussion is specifically about her sinus disease and quality of life rather than an urgent respiratory concern.
A new risk with nothing else pulling her toward it
Her situation is the one where I'd actually push back on desensitization as the default. She has no independent reason to accept indefinite high-dose aspirin's real bleeding and ulcer risk — she'd be taking on a wholly new chronic medication risk purely for her sinus disease.
That's fair, and it's a real difference from Walter's case — I wouldn't make the same recommendation for her that I made for him.
Dupilumab's AERD-specific subgroup data give her a real option that doesn't require accepting a new drug-class risk at all. For a patient with nothing else pulling her toward aspirin, that's the more proportionate first choice.
This is the cleanest possible illustration of why the same disease doesn't mean the same treatment — the drug being proposed is identical to Walter's, but the actual risk being accepted is categorically different when there's no independent indication making that risk one she'd be carrying either way.
Agreed: start dupilumab and hold aspirin desensitization as a later option only if biologic therapy proves inadequate, given she has no independent reason to accept aspirin's risks the way Walter does.
The group was explicit that this wasn't a disagreement about which drug works better in the abstract — both have real supporting data — but about which risk was proportionate to ask a specific patient to accept.